Related Experiment Video
Updated: Mar 26, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Advances in HSP27 and HSP90-targeting strategies for glioblastoma
Randy van Ommeren1, Michael D Staudt1, Hu Xu1
1Department of Clinical Neurological Sciences, Western University, 339 Windermere Road, Suite C7-134, London, ON, N6A 5A5, Canada.
Abstract:
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. There is a critical need for novel strategies to abolish the molecular mechanisms that support GBM growth, invasion and treatment resistance. The heat shock proteins, HSP27 and HSP90, serve these pivotal roles in tumor cells and have been identified as effective targets for developing therapeutics. Natural and synthetic inhibitors have been evaluated in clinical trials for several forms of systemic cancer but none as yet for GBM. This topic review summarizes the current preclinical evidence and rationale to define the potential of HSP27 and HSP90 inhibitors in GBM management.
Insights
Heat shock proteins HSP27 and HSP90 are key drivers of glioblastoma growth and resistance. Inhibitors targeting these proteins show promise for future glioblastoma treatments.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Glioblastoma (GBM) is a highly aggressive primary brain tumor in adults.
- GBM exhibits significant growth, invasion, and treatment resistance, necessitating novel therapeutic strategies.
- Heat shock proteins (HSPs), specifically HSP27 and HSP90, play crucial roles in supporting these malignant characteristics of GBM cells.
Purpose of the Study:
- To review preclinical evidence and rationale for targeting HSP27 and HSP90 in glioblastoma.
- To define the potential therapeutic value of HSP27 and HSP90 inhibitors in GBM management.
Main Methods:
- Literature review of preclinical studies on HSP27 and HSP90 inhibitors in glioblastoma.
- Analysis of the molecular mechanisms by which HSP27 and HSP90 contribute to GBM progression and treatment resistance.
Main Results:
- HSP27 and HSP90 are implicated in GBM cell proliferation, invasion, and survival.
- Inhibitors of HSP27 and HSP90 have demonstrated anti-tumor activity in preclinical GBM models.
- While evaluated in other cancers, HSP inhibitors have not yet been extensively studied for GBM.
Conclusions:
- HSP27 and HSP90 represent promising therapeutic targets for glioblastoma.
- Further investigation and clinical trials of HSP inhibitors are warranted for GBM treatment.
